Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03792139 · ClinicalTrials.gov registry record · Phase 1
An Interaction Study of LY3200882 in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03792139 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 23 participants.
The verdict
NCT03792139, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the effect of itraconazole on the amount of LY3200882 in the blood stream and how long the body takes to get rid of LY3200882. The safety and tolerability of LY3200882 when given with itraconazole will be evaluated. The study is expected to last up to 19 days from the first dose to follow-up (inclusive). Screening will occur up to 28 days prior to enrollment.
Interventions
- DRUG Itraconazole
- DRUG LY3200882
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-01-08 |
| Est. Completion | 2019-02-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03792139
The ClinicalTrials.gov registry entry for NCT03792139 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Itraconazole is the first listed.
NCT03792139 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03792139 about?
NCT03792139 is a clinical study titled "An Interaction Study of LY3200882 in Healthy Participants". The main purpose of this study is to evaluate the effect of itraconazole on the amount of LY3200882 in the blood stream and how long the body takes to get rid of LY3200882. The safety and tolerability of LY3200882 when given with itraconazole will be evaluated. The study is expected to last up to 19...
What is the current status of trial NCT03792139?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2019-01-08. Estimated completion is 2019-02-23.
What interventions are being tested in trial NCT03792139?
The interventions under investigation include: Itraconazole (DRUG), LY3200882 (DRUG).
Who is sponsoring clinical trial NCT03792139?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.